European Stocks Extend Winning Streak to Fifth Week as Novo Nordisk Soars

Deep News01-17

European stocks rose for a fifth consecutive week, as investors maintained their confidence in the sustained demand for artificial intelligence. Shares of Novo Nordisk A/S surged by 6.5% after UK regulators approved the use of higher dosages of its obesity drug.

The Europe Stoxx 600 index closed largely flat on the day, yet still managed to notch a 0.8% gain for the week. Energy and utilities sectors were the standout performers on Friday, while consumer goods and mining stocks lagged behind.

The luxury goods sector was weighed down by Richemont, after Bank of America downgraded the stock. Analysts indicated that foreign exchange volatility, gold prices, and tariff factors are exerting pressure on its profit margins.

European equities repeatedly hit new highs this week, as investors' persistent optimism regarding potential fiscal stimulus and economic growth overshadowed prevailing geopolitical concerns.

"Europe's growth outlook is improving, driven by German fiscal spending, and even if the pace of growth might be more moderate, European stocks still have room to rise," stated Wolf von Rotber, an equity strategist at Bank J. Safra Sarasin.

Market attention has now shifted to the corporate earnings season. Strategists from Goldman Sachs Group indicated that analysts expect a 1% year-over-year increase in fourth-quarter earnings for the Stoxx Europe 600 index constituents. However, excluding the financial sector, overall profits are projected to decline by 5%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment